AG Kwame Raoul led a bipartisan coalition of 37 states and territories urging the Food and Drug Administration (FDA) to take swift action against bad actors that are endangering consumers with counterfeit forms of the weight loss and diabetes drugs Mounjaro, Zepbound, Ozempic and Wegovy (GLP-1 drugs). “The usage of GLP-1 medications continues to increase as millions of Americans seek tools to help them lose weight and live healthier lifestyles. However, scammers and bad actors are attempting to take advantage of individuals looking for more affordable and convenient means of obtaining GLP-1 medications by selling them directly to consumers,” Raoul said. “Consumers who purchase what they think is a product containing the active ingredients found in name-brand GLP-1 drugs run the risk of taking a counterfeit drug that was never intended for human consumption. I am proud to co-lead this bipartisan coalition calling on the FDA to use its resources to take immediate action to protect Americans from the dangers of counterfeit versions of GLP-1 drugs.” 

News Detail Page